yahoo_financeOriginal article
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Data ReadoutpositiveTEV-749Positive
AI Analysis
Summary
Teva announced post hoc data for TEV-749, an olanzapine long-acting injectable formulation, demonstrating high stabilization rates and long-term efficacy as a once-monthly subcutaneous treatment for schizophrenia in adults.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Post hoc data highlighting high rates of stabilization and long-term efficacy for once-monthly subcutaneous injectable
Importance:5/10
Sentiment:
0.60
olanzapineLAIlong-acting injectableschizophreniapost hoc analysispsychiatry
Related Companies
Read the original article
Published by yahoo_finance on September 18, 2026 8:30 PM